Latest MedImmune Stories
CRANBURY, N.J., Aug. 4, 2011 /PRNewswire/ -- Palatin Technologies, Inc.
DALLAS, August 4, 2011 /PRNewswire/ -- ReportsnReports announces it will carry reports on Needle-Free Drug Delivery Market & Hospital-Acquired Infections (HAI) Diagnostics Market in its store A.Needle-Free Drug Delivery: The Market for Alternatives to Needle-Based Systems for Vaccine and Biologics [http://www.reportsnreports.com/reports/117995-needle-free-drug-delivery-the-market-for-alternatives-to-needle-.html ] The coming decade will see drug delivery...
Researchers from Australia determined that pediatric liver transplant patients who received a single-dose of the H1N1 vaccine were not adequately protected against the virus compared to healthy children.
GAITHERSBURG, Md., July 18, 2011 /PRNewswire/ -- MedImmune announced today that it has begun shipping FluMistÂ® (Influenza Vaccine Live, Intranasal) to influenza vaccine distributors who service health care providers throughout the United States.
GAITHERSBURG, Md., July 18, 2011 /PRNewswire/ -- MedImmune has received confirmation from the U.S.
Swine flu may be able to be detected through a simple breath test.
- Phase II part B confirms results obtained in Phase II part A - - Company's results continue to be amongst the best for influenza vaccine manufacturing technologies - QUEBEC CITY, June 30, 2011 /PRNewswire/ - Medicago Inc.
BANGALORE, India, June 23, 2011 /PRNewswire/ -- Jubilant Biosys Ltd., Bengaluru, based subsidiary of Jubilant Life Sciences Ltd., and AstraZeneca, today announced another successful delivery of an early stage milestone in the Pain therapeutic area. The collaboration, initiated two years ago in the Neuroscience therapeutic area, has now expanded to Cardiovascular and Metabolic diseases and focuses on the delivery of a steady stream of preclinical outcomes to AstraZeneca,...
NESS ZIONA, Israel, June 16, 2011 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (TASE: BNDX) [http://www.biondvax.com ] today announced positive results from its first Phase II clinical trial of the Multimeric-001 Universal Influenza Vaccine.
- All tested doses were found safe and well-tolerated - - A single dose of 5 Âµg met the 3 CHMP immunogenicity criteria - QUEBEC CITY, June 8, 2011 /PRNewswire/ - Medicago Inc.
- The analysis of literature, focusing on the words and grammar to the exclusion of context or literary merit.